Inovio reports FY2024 net loss $107.3M; on track for INO-3107 BLA submission mid-2025

INOVIO PHARMACEUTICALS, INC.

Net loss $19.4M Q4 ($0.65/share) and $107.3M FY ($3.95/share), narrower than 2023's $135.1M.
Cash, equivalents & investments $94.1M at Dec 31, 2024, down from $145.3M at Dec 31, 2023.
BLA for INO-3107 (RRP) on track for rolling submission mid-2025; device verification testing complete H1 2025.
DMAb interim data: 100% of participants (24/24) maintained antibody levels at week 72; no anti-drug antibodies.
Raised >$72M from ATM and two equity offerings in 2024; cash runway into Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.